(Q34097937)

English

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

James H. Godbold

7

object named as

James Godbold

1 reference

Europe PubMed Central

31 July 2017

author name string

Matthew D Galsky

1

1 reference

Europe PubMed Central

31 July 2017

Marshall Posner

2

1 reference

Europe PubMed Central

31 July 2017

Randall F Holcombe

3

1 reference

Europe PubMed Central

31 July 2017

Karen M Lee

4

1 reference

Europe PubMed Central

31 July 2017

Krzysztof Misiukiewicz

5

1 reference

Europe PubMed Central

31 July 2017

Che-Kai Tsao

6

1 reference

Europe PubMed Central

31 July 2017

Rothschild Soto

8

1 reference

Europe PubMed Central

31 July 2017

Kiev Gimpel-Tetra

9

1 reference

Europe PubMed Central

31 July 2017

Nancy Lowe

10

1 reference

Europe PubMed Central

31 July 2017

William K Oh

11

1 reference

Europe PubMed Central

31 July 2017

publication date

15 July 2014

1 reference

Europe PubMed Central

31 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

31 July 2017

74

1 reference

Europe PubMed Central

31 July 2017

465-471

1 reference

Europe PubMed Central

31 July 2017

3

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-014-2518-5

0 references

Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Comprehensive molecular characterization of urothelial bladder carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Targeting the tumour vasculature: insights from physiological angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Fibroblast growth factor signalling: from development to cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Patterns of somatic mutation in human cancer genomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

VEGF and the quest for tumour angiogenesis factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146643

5 July 2018

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2518-5

21 January 2018

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2518-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2518-5

21 January 2018

Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed

1 reference

https://pubmed.ncbi.nlm.nih.gov/25023489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25023489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-014-2518-5

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34097937&oldid=2091845562"